Vascular Therapies, Inc.

Vascular Therapies, Inc. focuses on developing innovative solutions to enhance vascular access for hemodialysis patients, primarily through its flagship product, Sirogen™, which delivers targeted drug therapy directly to vascular sites. Founded in 2001 and headquartered in Cresskill, US, Vascular Therapies, Inc. specializes in creating solutions for vascular access.

The company raised USD 23. 96 mn in Series F funding on February 18, 2022, which brought the total amount raised to USD 23. 96 mn. The CEO of the company is John McDermott.

Vascular Therapies specializes in innovative solutions for improving vascular access in hemodialysis patients. The company’s core product, Sirogen™, is a bioabsorbable implant designed to deliver sirolimus, a drug known to prevent blood vessel narrowing, directly to the site of arteriovenous fistulas. This intervention aims to enhance the usability of fistulas for successful hemodialysis while minimizing the time required for these access points to mature and be ready for use. Additionally, the company addresses significant complications associated with traditional vascular access methods, such as central venous catheters and arteriovenous grafts, by providing options that reduce the risk of infection and thrombosis.

Their offerings primarily target the U. S. market, catering to hemodialysis patients, dialysis providers, and healthcare professionals, thereby improving the overall patient experience and health outcomes. The revenue structure for Vascular Therapies is centered on the sales of its flagship product, Sirogen™, to healthcare facilities and providers in the dialysis sector.

Transactions typically occur through direct sales to hospitals and dialysis clinics, where the product is integrated into surgical procedures involving the creation of arteriovenous fistulas. The company engages in B2B transactions, focusing on partnerships with medical institutions that provide dialysis treatment. Pricing plans for Sirogen™ are based on competitive industry standards for medical implants, reflecting the value provided in enhancing patient outcomes and addressing vascular access challenges. The adoption of Sirogen™ in clinical settings further supports revenue generation through increased demand for improved vascular access solutions in the healthcare market.

In February 2022, Vascular Therapies, Inc. raised USD 23. 96 mn in Series F funding from unspecified investors to accelerate its Sirogen™, a proprietary sirolimus formulation for intraoperative, local, perivascular drug delivery. The company plans to expand its reach by introducing this innovative product to new markets and regions, further enhancing its product offerings for vascular access in hemodialysis.